FDA clears PENS device for relief of post-op pain of cesarean section
The US Food and Drug Administration has cleared a novel percutaneous electrical neurostimulation (PENS) device Primary Relief for symptomatic relief of postoperative pain following caesarean section delivery.The manufacturing company DyAnsys, Inc., has announced that Primary Relief, a percutaneous electrical neurostimulation device, has been cleared to treat pain following a...
The US Food and Drug Administration has cleared a novel percutaneous electrical neurostimulation (PENS) device Primary Relief for symptomatic relief of postoperative pain following caesarean section delivery.
The manufacturing company DyAnsys, Inc., has announced that Primary Relief, a percutaneous electrical neurostimulation device, has been cleared to treat pain following a Caesarean-section (C-section).
The percutaneous electrical nerve stimulator (PENS) system can be used for up to three days for symptomatic relief of post-operative pain following a C-section delivery.
"This device has been shown to make a difference for patients, effectively relieving pain without reliance on opioids or other analgesics. This is a significant advancement in providing options to women," said DyAnsys Chief Executive Srini Nageshwar. "We look forward to connecting with physicians and hospitals to providing this alternative to their patients."
The wearable, battery-operated device is designed to administer periodic low level electrical pulses to the ear over 72 hours from the activation of the device. The electrical pulses are delivered to branches of the cranial nerves on the ear through a wire assembly and stimulation needles.
The effectiveness of the device was demonstrated in a single-center, double arm, randomized, controlled, parallel assignment prospective study involving 44 participants who underwent C-section delivery.
The analysis showed that minimally invasive nerve stimulation intervention using Primary Relief device reduced the pain score faster than the standard analgesics. No additional opioid analgesics were required. No complications or adverse events were observed in any of the participants during the study period.
The nonclinical testing of Primary Relief device included biocompatibility testing, electrical safety (electromagnetic compatibility and safety), performance bench testing and software verification and validation.
FDA clears DyAnsys neurostimulation device primary relief to treat C-section pain. News release. DyAnsys, Inc. Accessed July 28, 2022. https://www.prnewswire.com/news-releases/fda-clears-dyansys-neurostimulation-device-primary-relief-to-treat-c-section-pain-301595255.html
Primary Relief 510(k) summary. Food and Drug Administration. Accessed July 28, 2022. https://www.accessdata.fda.gov/cdrh_docs/pdf21/K213188.pdf
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Before Joining Medical Dialogues, he has served at important positions in the medical industry in India including as the Hony. Secretary of the Delhi Medical Association as well as the chairman of Anti-Quackery Committee in Delhi and worked with other Medical Councils in India. Email: email@example.com. Contact no. 011-43720751